Bruker Corporation (NASDAQ:BRKR) Receives Consensus Rating of “Hold” from Brokerages

Bruker Corporation (NASDAQ:BRKR) has earned an average rating of “Hold” from the fifteen analysts that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $50.3846.

A number of research analysts recently commented on BRKR shares. Wells Fargo & Company boosted their price target on Bruker from $48.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Barclays decreased their target price on shares of Bruker from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, February 13th. Wolfe Research upgraded shares of Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 target price for the company in a research report on Wednesday, December 10th. Zacks Research upgraded shares of Bruker from a “strong sell” rating to a “hold” rating in a research report on Monday, December 8th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a research note on Monday, December 29th.

Insider Buying and Selling

In other news, VP Mark Munch sold 7,000 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $55.00, for a total value of $385,000.00. Following the completion of the transaction, the vice president directly owned 128,443 shares in the company, valued at approximately $7,064,365. This represents a 5.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 11,000 shares of company stock valued at $554,280. 27.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Bruker

A number of institutional investors have recently made changes to their positions in the stock. Los Angeles Capital Management LLC bought a new stake in Bruker during the fourth quarter valued at $26,000. Allworth Financial LP raised its position in shares of Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares in the last quarter. Parallel Advisors LLC lifted its stake in shares of Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 479 shares during the period. Spire Wealth Management boosted its position in shares of Bruker by 85.3% during the 3rd quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 665 shares in the last quarter. Finally, Summit Securities Group LLC bought a new stake in shares of Bruker during the 4th quarter valued at about $50,000. Institutional investors own 79.52% of the company’s stock.

Bruker Trading Down 0.9%

Shares of BRKR stock opened at $33.33 on Monday. The stock has a market cap of $5.07 billion, a P/E ratio of -222.17, a price-to-earnings-growth ratio of 2.00 and a beta of 1.19. Bruker has a 1 year low of $28.53 and a 1 year high of $56.22. The company has a current ratio of 1.73, a quick ratio of 0.87 and a debt-to-equity ratio of 0.75. The stock has a 50 day simple moving average of $41.57 and a 200 day simple moving average of $41.14.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). The company had revenue of $977.20 million for the quarter, compared to the consensus estimate of $964.61 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.Bruker’s revenue was down .2% on a year-over-year basis. During the same quarter last year, the business earned $0.76 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, research analysts predict that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd will be issued a $0.05 dividend. The ex-dividend date of this dividend is Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. Bruker’s dividend payout ratio is -133.33%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.